Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2021 01:00 ET | Source: ObsEva SA

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i; agent is being studied in an area of significant unmet need Ad hoc...
July 02, 2021 01:00 ET | Source: ObsEva SA

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia– GENEVA, Switzerland and BOSTON – July 2,...
June 30, 2021 01:00 ET | Source: ObsEva SA

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting

-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo...
June 24, 2021 01:00 ET | Source: ObsEva SA

ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting

- Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Top-line data from pilot study of Yselty for the treatment of...
June 10, 2021 01:00 ET | Source: ObsEva SA

ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021

-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation- - Phase 2b/3 adaptive dose-ranging study planned to initiate in Q4:21- ...
June 02, 2021 01:00 ET | Source: ObsEva SA

ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021

- Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an oral presentation - GENEVA, Switzerland and BOSTON, MA – June 2, 2021 –...
May 31, 2021 01:00 ET | Source: ObsEva SA

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021

Geneva, Switzerland and Boston, MA – May 31, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
May 25, 2021 16:05 ET | Source: ObsEva SA

ObsEva Announces Proposed Changes to the Composition of its Board of Directors

Geneva, Switzerland and Boston, MA – May 25, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
May 20, 2021 01:00 ET | Source: ObsEva SA

ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

-PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment- -Results continue...
May 06, 2021 01:00 ET | Source: ObsEva SA

ObsEva Announces First Quarter 2021 Financial Results and Business Update

-Yselty® for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Yselty® for endometriosis: Readout from...